Bress, Adam P., PharmD, MS

Research Interests

  • Health Disparities
  • Pharmacoepidemiology
  • Pharmacogenetics
  • Cardiovascular Disease Prevention and Treatment
  • Hypertension
  • Heart Failure

Languages

  • English

Academic Information

  • Departments: Population Health Sciences - Assistant Professor
  • Divisions: Health System Innovation and Research

Academic Office Information

  • Williams Building
    295 Chipeta Way
    Salt Lake City, UT 84108

Academic Bio

Dr. Bress is an Assistant Professor of Population Health Sciences in the Division of Health System Innovation and Research and an Investigator at the VA Salt Lake City Health Care System.

Dr. Bress received his Doctor of Pharmacy degree from the University of Maryland, and his Masters of Science in Clinical and Translational Science from the University of Illinois at Chicago School of Public Health with a focus on epidemiology. He completed his residency in pharmacy practice at Yale-New Haven Hospital and Cardiology at the University of Illinois at Chicago. He subsequently completed his post-doctoral research fellowship in cardiovascular pharmacogenomics at the University of Illinois at Chicago.

Dr. Bress is a formally-trained cardiovascular clinical pharmacist and population scientist. His research is focused on the prevention and treatment of cardiovascular disease, optimizing medication use, and reducing health disparities. He is particularly interested in studying antihypertensive medication use, responses, and outcomes to help patients and providers, as well as health systems, payers, governments, and population health managers make better decisions about how to treat and control high blood pressure. He is also interested in genetic ancestry and racial/ethnic differences in antihypertensive medication responses.

Dr. Bress's research is currently NIH-funded as Principal Investigator by a K01 (K01HL133468) and R01 (R01HL139837) from the NHLBI. He is also PI of an NHLBI R13 Conference grant (R13HL144012) to support the University of Utah Translational Hypertension Symposium. Dr. Bress's research has been published as first author in the New England Journal of Medicine, The Journal of the American College of Cardiology, and Circulation and has been covered in TIME Magazine, The New York Times, and CBS radio.

Dr. Bress has established collaborations with a multi-disciplinary team of investigators in hypertension, cardiology, health services research, epidemiology, and pharmacogenetics at the University of Utah and around the country. He is an active member of the hypertension working groups for two ongoing NIH-funded cohort studies including the Jackson Heart Study (JHS) and the Coronary Artery Risk Development in Young Adults (CARDIA) Study. He is also an active member of the Systolic Blood Pressure Intervention Trial (SPRINT) Research Group.

Dr. Bress has received peer-reviewed extramural research support as Principal Investigator (PI) from the National Institutes of Health (NIH) specifically from the National Heart, Lung, and Blood Institute (NHLBI). He is currently PI of a five-year K01 award which is determining the association between genetic ancestry, including individual genetic variants, with blood pressure control, antihypertensive medication responses, and cardiovascular disease outcomes in African Americans. This project will identify genetic factors that may account for observed racial differences in antihypertensive medication response, potentially identify new approaches for optimizing antihypertensive medication prescribing and thereby improve blood pressure control rates in African Americans. His mentors and scientific advisors for this award are Lynn Jorde (human genetics), Rachel Hess (health services research), Rick Kittles (genetic ancestry and health disparities), Donna Arnett (pharmacogenetics), Paul Muntner (hypertension epidemiology), and Tom Greene (biostatistics).

He also received grant support from the biomedical industry as PI for investigator-initiated research projects focused on cardiovascular pharmacoepidemiology.

Research Statement

I am a cardiovascular clinical pharmacist with training in epidemiology and pharmacogenetics. We focus on disparities in prevention and treatment of cardiovascular disease with a focus on hypertension and antihypertensive medication use. Using pharmacoepidemiology and pharmacogenetics, we try to better understand causes of racial differences in medication responses and outcomes. We apply these findings to understand the population-level impact, generalizability, and cost-effectiveness in diverse groups.

Education History

Type School Degree
Graduate Training University of Illinois at Chicago School of Public Health
Clinical and Translational Science
M.S.
Research Fellow University of Illinois at Chicago
Cardiovascular Pharmacogenomics
Research Fellow
Residency University of Illinois at Chicago
Cardiology
Resident
Residency Yale-New Haven Hospital
Pharmacy Practice
Resident
Doctoral Training University of Maryland
Pharmacy
Pharm.D.

Global Impact

Presentations

Description Country
Featured Faculty, "Optimizing antihypertensive treatment in 2017: Lessons using pharmacoepidemiology and pharmacoeconomics", China Heart Congress, Beijing, China, August 10th, 2017 China

Selected Publications

Journal Article

  1. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintrab WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski N, Tamariz L, King JB (). Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes. Hypertension, In Press.
  2. Tajeu GS, Kent ST, Guang L, Bress AP, Cuffee Y, Halpern MT, Kronish IM, Krousel-Wood M, Mefford MT, Shimbo D, Muntner P (). Trends in Antihypertensive Medication Nonpersistence and Low Adherence among US Adults <65 years of age with Commercial Health Insurance Initiating Treatment Between 2007 and 2014. Hypertension, In Press.
  3. He KY, Li X, Kelly TN, Liang J, Cade BE, Assimes TL, Becker LC, Beitelshees AL, Bress AP, Chang YC, Chen YI, de Vries PS, Fox ER, Franceschini N, Furniss A, Gao Y, Guo X, Haessler J, Hwang SJ, Irvin MR, Kalyani RR, Liu CT, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe S, Palmas W, Reiner AP, Shimbo D, Smith JA, Snively BM, Yanek LR, Boerwinkle E, Correa A, Cupples LA, He J, Kardia SLR, Kooperberg C, Mathias RA, Mitchell BD, Psaty BM, Vasan RS, Rao DC, Rich SS, Rotter JI, Wilson JG, Chakravarti A, Morrison AC, Levy D, Arnett DK, Redline S, Zhu X (2019 Feb). Leveraging linkage evidence to identify low-frequency and rare variants on 16p13 associated with blood pressure using TOPMed whole genome sequencing data. Hum Genet, 138(2), 199-210.
  4. Jaeger BC, Anstey DE, Bress AP, Booth JN 3rd, Butler M, Clark D 3rd, Howard G, Kalinowski J, Long DL, Ogedegbe G, Plante TB, Shimbo D, Sims M, Supiano MA, Whelton PK, Muntner P (2019 Feb). Cardiovascular Disease and Mortality in Adults Aged >/=60 Years According to Recommendations by the American College of Cardiology/American Heart Association and American College of Physicians/American Academy of Family Physicians. Hypertension, 73(2), 327-334.
  5. Bress AP, Colantonio LD, Cooper RS, Kramer H, Booth JN 3rd, Odden MC, Bibbins-Domingo K, Shimbo D, Whelton PK, Levitan EB, Howard G, Bellows BK, Kleindorfer D, Safford MM, Muntner P, Moran AE (2019 Jan 2). Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation, 139(1), 24-36.
  6. Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, Gidding SS, Bress AP, Greenland P, Muntner P, Lloyd-Jones DM (2018 Nov 6). Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life. JAMA, 320(17), 1774-1782.
  7. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman WC (2018 Sep 18). Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. J Am Heart Assoc, 7(18), e009326.
  8. Bress AP, Dodson JA, King JB, Sauer BC, Reese T, Crook J, Radwanski P, Knippenberg K, Greene T, Nelson RE, Munger MA, Weintraub WS, LaFleur J (2018 Dec 1). Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris. Am J Cardiol, 122(11), 1809-1816.
  9. Colantonio LD, Booth JN 3rd, Bress AP, Whelton PK, Shimbo D, Levitan EB, Howard G, Safford MM, Muntner P (2018 Sep 11). 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk. J Am Coll Cardiol, 72(11), 1187-1197.
  10. Yang S, Ambrosius WT, Fine LJ, Bress AP, Cushman WC, Raj DS, Rehman S, Tamariz L (2018 Jun). A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes. Clin Trials, 15(3), 305-312.
  11. LaFleur J, Bress AP, Myers J, Rosenblatt L, Crook J, Knippenberg K, Bedimo R, Tebas P, Nyman H, Esker S (2018 Jun). Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. Infect Dis Ther, 7(2), 293-308.
  12. Booth JN III, Li M, Shimbo D, Hess R, Irvin MR, Kittles R, Wilson JG, Jorde LB, Cheung AK, Lange LA, Lange EM, Yano Y, Muntner P, Bress AP (2018 May 7). West African Ancestry and Nocturnal Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens, 31(6), 706-714.
  13. Irvin MR, Booth JN 3rd, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P (2018 Mar). The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich), 20(3), 438-446.
  14. LaFleur J, Bress AP, Esker S, Knippenberg K, Crook J, Nyman H, Bedimo R, Tebas P, Rosenblatt L (2018 Mar 1). Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. J Acquir Immune Defic Syndr, 77(3), 325-330.
  15. Still CH, Rodriguez CJ, Wright JT Jr, Craven TE, Bress AP, Chertow GM, Whelton PK, Whittle JC, Freedman BI, Johnson KC, Foy CG, He J, Kostis JB, Lash JP, Pedley CF, Pisoni R, Powell JR, Wall BM (2017 Dec 8). Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. Am J Hypertens, 31(1), 97-107.
  16. Butler MJ, Tanner RM, Muntner P, Shimbo D, Bress AP, Shallcross AJ, Sims M, Ogedegbe G, Spruill TM (2017 Sep). Adherence to antihypertensive medications and associations with blood pressure among African Americans with hypertension in the Jackson Heart Study. J Am Soc Hypertens, 11(9), 581-588.e5.
  17. Laing P, Bress AP, Fang J, Peterson K, Adler DG, Gawron AJ (2017 Dec 1). Trends in diagnoses after implementation of the Chicago classification for esophageal motility disorders (V3.0) for high-resolution manometry studies. Dis Esophagus, 30(12), 1-6.
  18. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD, Morris AK, Kholmovski EG, Marrouche N (2017 Sep 12). Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol, 70(11), 1311-1321.
  19. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negron N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE (2017 Aug 24). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 377(8), 745-755.
  20. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V (2017 Aug 9). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.LID - dc170885 [pii]LID - 10.2337/dc17-0885 [doi]. (Epub ahead of print) Diabetes Care.
  21. LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C (2017 Sep 24). Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS, 31(15), 2095-2106.
  22. Booth JN 3rd, Abdalla M, Tanner RM, Diaz KM, Bromfield SG, Tajeu GS, Correa A, Sims M, Ogedegbe G, Bress AP, Spruill TM, Shimbo D, Muntner P (2017 Aug). Cardiovascular Health and Incident Hypertension in Blacks: JHS (The Jackson Heart Study). Hypertension, 70(2), 285-292.
  23. Shallcross AJ, Butler M, Tanner RM, Bress AP, Muntner P, Shimbo D, Ogedegbe G, Sims M, Spruill TM (2017 Jul). Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study. J Hum Hypertens, 31(7), 474-478.
  24. King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP (2017 Jun). Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. Pharmacotherapy, 37(6), 662-672.
  25. Bress AP, Colantonio LD, Booth JN 3rd, Spruill TM, Ravenell J, Butler M, Shallcross AJ, Seals SR, Reynolds K, Ogedegbe G, Shimbo D, Muntner P (2017 Feb 8). Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks.LID - e005054 [pii]LID - 10.1161/JAHA.116.005054 [doi]. J Am Heart Assoc, 6(2).
  26. Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, Bansal VK, Cao G, Yee J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS (2017 Apr 25). Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation, 135(17), 1617-1628.
  27. Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, Marpadga R, Gheith H, Kim Y, Li Y, Cavallari L, Stamos TD (2017 May). Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. Clin Cardiol, 40(5), 314-321.
  28. Ravenell J, Shimbo D, Booth JN 3rd, Sarpong DF, Agyemang C, Beatty Moody DL, Abdalla M, Spruill TM, Shallcross AJ, Bress AP, Muntner P, Ogedegbe G (2017 Jun 20). Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study. Circulation, 135(25), 2470-2480.
  29. Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016 Jul 12). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke.LID - 10.1161/JAHA.116.003547 [doi]LID - e003547 [pii]. J Am Heart Assoc, 5(7).
  30. Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, Shimbo D, Muntner P (2016 Sep). Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension, 68(3), 565-75.
  31. Stone RH, Bress AP, Nutescu EA, Shapiro NL (2016 Aug). Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic. Ann Pharmacother, 50(8), 637-44.
  32. Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J (2016). The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ, 19(3), 213-28.
  33. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P (2016 Feb 9). Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol, 67(5), 463-72.
  34. Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH (2016 Sep). Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. J Card Fail, 22(9), 692-9.
  35. Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016 Feb). Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Pharmacotherapy, 36(2), 174-86.
  36. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK (2016 May). Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail, 4(5), 392-402.
  37. Bress A, Kittles R, Wing C, Hooker SE Jr, King A (2015 Jun). Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics, 25(6), 305-12.
  38. Sharabiani A, Bress A, Douzali E, Darabi H (2015). Revisiting Warfarin Dosing Using Machine Learning Techniques. Comput Math Methods Med, 2015, 560108.
  39. Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, Brixner D (2015 Nov). Value Assessment for Genetic Testing of Drug Variation In An Elderly Population. Value Health, 18(7), A747.
  40. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH (2015 Feb). Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics, 25(2), 73-81.
  41. King JB, Bress AP, Reese AD, Munger MA (2015 Sep). Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy, 35(9), 823-37.
  42. McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA (2014 Jun). Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy, 34(6), 561-9.
  43. DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL (2014 Nov). Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy, 34(11), 1121-31.
  44. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH (2013). Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS ONE, 8(7), e71268.
  45. Kane SP, Bress AP, Tesoro EP (2013 May). Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother, 47(5), 628-36.
  46. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH (2013 Nov). Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy, 33(11), 1156-64.
  47. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012 Dec). Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics, 13(16), 1925-35.
  48. Bress AP, Filtz MR, Truong HA, Nalder M, Vienet M, Boyle C (). An Advanced Pharmacy Practice Experience in Melbourne, Australia: Practical Guidance for Global Experiences. Curr Pharm Teach Learn, 1(3), 53-62.
  49. Cavallari LH, Jeong H, Bress A (2011). Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med, 4, 123-36.

Book Chapter

  1. Bress AP, Cavallari LH, Didomenico RJ (). Ischemic Heart Disease. In Katz MD, Matthias KR, Chisholm-Burns MA (Eds.), Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach (4th Edition). New York: McGraw-Hill Companies, Inc.
  2. Bress AP, Cavallari LH, Didomenico RJ (). Ischemic Heart Disease. In Katz MD, Matthias KR, Chisholm-Burns MA (Eds.), Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach (Third Edition, pp. 31-4). New York: McGraw-Hill Companies, Inc.

Conference Proceedings

  1. Sharabiani A, Darabi H, Bress A, Cavallari L, Nutescu E, Drozda K (). Machine learning based prediction of warfarin optimal dosing for African American patients. IEEE International Conference on Automation Science and Engineering (CASE).

Editorial

  1. Bress AP, King JB (2019 Mar 5).

    Optimizing Medical Therapy in Chronic Worsening HFrEF: A Long Way to Go.

    . J Am Coll Cardiol, 73(8), 945-947.
  2. Bress AP, Irvin MR, Muntner P (2017 Jun). Genetics of Blood Pressure: New Insights Into a Complex Trait. Am J Kidney Dis, 69(6), 723-725.

Letter

  1. Bress AP, Papademetriou V, Feinglos MN (2018 Jun). Response to Comment on Bress et al. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care 2017;40:1401-1408 [Letter to the editor]. Diabetes Care, 41(6), e90-e91.
  2. Bellows BK, Bress AP, Moran A (2017 Nov 30). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control [Letter to the editor]. N Engl J Med, 377(22), 2199-2200.
  3. Bress AP, Kramer H, Cooper RS (2017 Sep 19). Response by Bress et al to Letters Regarding Article, "Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections from NHANES (National Health and Nutrition Examination Survey)" [Letter to the editor]. Circulation, 136(12), 1174-1175.
  4. King J, Bress A, Bellows B (2017 Apr 18). Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction [Letter to the editor]. Ann Intern Med, 166(8), 606-607.
  5. Kane SP, Bress AP, Tesoro EP (2013 Dec). Author response to Brown et al characterization of free phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation [Letter to the editor]. Ann Pharmacother, 47(12), 1744.

Abstract

  1. Reynolds K, Shimbo D, Bowling CB, Deng L, Bress A, Sim J, Muntner P (2016). OS 16-06 RISK FACTORS FOR SERIOUS FALL INJURIES FOLLOWING INITIATION OF ANTIHYPERTENSIVE MEDICATION [Abstract]. J Hypertens, 34 Suppl 1 - ISH 2016 Abstract Book, e219-e220.
  2. Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups [Abstract]. J Am Soc Hypertens, 10(1), e6-e7.
  3. McConeghy K, Bress AP, Wing C (). Reports of Bleeding-Related Fatalities with Dabigatran and Warfarin: An Analysis Using the Food and Drug Administration Adverse Events Reporting System. Podium presentation at the Annual Scientific Sessions of the American College of Cardiology, San Francisco, CA [Abstract]. J Am Coll Cardiol, 61(10S).
  4. Bress AP, Patel SR, Desai AA, Mansour I, Groo VJ, Han J, Progar K, Shah E, Stamos T, Garcia JG, Kittles RA, Cavallari LH (). Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) with Atrial Fibrillation in African–Americans with Heart Failure; also presented as a poster at the Annual Scientific Sessions of the American College of Cardiology, March 2013, San Francisco, CA [Abstract]. J Am Coll Cardiol, 61(10S).
  5. Badawi O, Holl R, Hassan E, Zubrow M, Bress A (). Severe Sepsis (SS) is underreported in the ICU; also presented as a poster at the 37th Society of Critical Care Medicine Critical Care Congress, Honolulu, HI [Abstract]. Crit Care Medicine, 35, A256, (#918).

Other

  1. Patel T, Bress AP, Ismail S, Shroff A (). Sticky Platelets: Using platelet reactivity testing to guide anti-platelet therapy post PCI. Cardiac Interventions Today.
  2. Patel H, Bress AP, Shroff A (). Personalizing Oral Antiplatelet Therapy in PCI. Cardiac Interventions Today.

Video/Film/CD/Web/Podcast

  1. Bress A (). Maryland Pharmacy Students Blaze the Trail in Global Education [Web]. Baltimore, MD: University of Maryland at Baltimore. Available: http://www.oea.umaryland.edu/communications/news/?ViewStatus=FullArticle&articleDetail=6015.